Aerosolized NONOates have been investigated in animal models in acute pulmonary hypertension, but none have been used in humans. We report the first use of aerosolized diethylenetriamine nitric oxide adduct (DETA/NO), a NONOate, in a patient with severe acute respiratory distress syndrome. Both pulmonary vascular resistance index and mean pulmonary arterial pressure were reduced by a mean of 26% and 18% respectively after the administration of a single dose of DETA/NO (150 µmol). Intrapulmonary shunting also improved. There were no significant changes in systemic arterial pressure or arterial methaemoglobin concentration after DETA/NO inhalation. We conclude that DETA/NO aerosol produced selective pulmonary vasodilation, with an improvement in pulmonary haemodynamics and oxygenation, while having no measurable effect on the systemic circulation.
Selective pulmonary vasodilators (SPVs), such as inhaled nitric oxide (NO) 1 and inhaled aerosolized prostacyclin 2 have been used in patients with the acute respiratory distress syndrome (ARDS). SPVs reduce pulmonary hypertension without causing systemic hypotension and reduce intrapulmonary shunting, with an improvement in oxygenation 3 . NONOates are a group of novel compounds that have been tested for their selective pulmonary vasodilatory effect in animal models of pulmonary hypertension, both in our laboratories (Lam et al, submitted for publication) and elsewhere 4 . NONOates in time may prove to be superior to gaseous NO as SPVs because their long NO-release half-lives allow intermittent therapy, and because rebound pulmonary hypertension is theoretically less likely. In addition, NONOates are stable in solid form and highly water-soluble. This enables them to be delivered into the lung using a small volume nebulizer without the need for elaborate monitoring systems.
NONOates are chemical compounds that carry the [N(O)NO]functional group and spontaneously release NO at a predictable rate from aqueous solutions 5 . The half-lives of these compounds for generating NO vary from one minute to one day under normal physiological conditions. Diethylenetriamine nitric oxide adduct (DETA/NO) has a NO-generating half-life of approximately 20 h at 37°C 5 . Compared to the extremely short biological half-life of NO (less than five seconds), the slow and continuous release of NO from this novel compound potentially makes it a very useful therapeutic agent in patients with ARDS. However, the actual effects of aerosolized NONOates in patients with ARDS, which is a more complex physiological environment than that produced in animal studies so far, have not been previously reported 4 .
We report the immediate haemodynamic and oxygenation effects of the first use of aerosolized DETA/NO in a patient with severe ARDS.
CASE REPORT
A 72-year-old male was admitted to our hospital with pneumonia and right hilar abscess. He had excessive use of alcohol and had recently been diagnosed with small cell carcinoma of the lung. The carcinoma had been treated with chemotherapy and cranial irradiation. He presented with acute type I respiratory failure one day after admission to hospital and was transferred to the Intensive Care Unit (ICU) for mechanical ventilation and ongoing care of his respiratory failure. By day 7 after ICU admission, his pulmonary condition had deteriorated, with bilateral alveolar infiltrates on chest radiograph and a partial pressure of arterial oxygen to fraction of inspired oxygen concentration ratio (P a O 2 /FiO 2 ) of 120 mmHg. A pulmonary artery (PA) catheter was inserted and the initial pulmonary artery wedge pressure (PAWP) was 9 mmHg. The initial Murray Lung Injury Score and APACHE II scores were 3 and 15 respectively. The patient had received no vasopressor, inotrope or bronchodilator therapy for at least 12 hours before the administration of DETA/NO.
Approval from the Human Research Ethics Committee of Sir Charles Gairdner Hospital and written informed consent from the legal patient surrogate were obtained prior to study drug administration. The patient was ventilated with an FiO 2 of 0.5. Minute ventilation was adjusted to maintain pH in the range 7.35-7.40 (P a CO 2 <60 mmHg). Peak inflation pressure was maintained below 40 cmH 2 O, with a mean tidal volume of 8 ml/kg. Positive endexpiratory pressure was maintained at 13 cmH 2 O. Ventilator parameters were not altered for eight hours following test drug administration to provide a stable baseline. Mean central venous pressure (CVP), pulmonary arterial pressure (mean PAP), and pulmonary arterial wedge pressure (PAWP) were measured using a five-lumen 7.5 French gauge, balloon-tippped, flow-directed PA catheter (Arrow, Model AH-05050-H, Arrow International, U.S.A.) placed in the right pulmonary artery. Cardiac output (CO) was measured using the standard thermodilution technique. Values of CO were divided by body surface area (m 2 ) to obtain a cardiac index (CI), expressed in units of l/min/m 2 . Pulmonary vascular resistance index (PVRI) was calculated as 79.9 x (PAP-PCWP) x CI, expressed in units of dyn.s.cm -5 .m -2 . A catheter was inserted into the right radial artery and systemic blood pressure (SBP) was continuously monitored. Blood samples were drawn from the radial arterial line ("arterial") and the right atrial port of the PA catheter ("mixed venous"). Blood gases and methaemoglobin were measured using a blood gas analyser (ABL 520, Radiometer, Denmark). Values of intrapulmonary shunt (%) and alveolar-arterial oxygen partial pressure gradient (A-aDO 2 , mmHg) were calculated using the standard equations. Baseline values for haemodynamic parameters and blood gases were made at both 30 min and immediately before the start of DETA/NO delivery.
DETA/NO (150 µmol, Sigma Chemical, MO, U.S.A.) solution (final concentration of 30 mM) was freshly prepared by dissolving the drug in 5 ml of phosphate buffer (WA Hospital Central Pharmaceutical Manufacturing Facility, Perth, Australia, pH 7.4). The dose used in this study was derived from our previous study in a pig model of acute pulmonary hypertension, adjusted for body weight (Lam et al, submitted for publication). DETA/NO solution was aerosolized into the lungs via a Sidestream Jet Nebuliser (Medic-Aid Ltd., U.K.) driven by 100% oxygen at a flow rate of 3 l/min over 20 min. After the commencement of the drug administration, haemodynamic parameters and blood gases were measured every 15 min for the first two hours and then every 30 min for a further two hours.
Measures of haemodynamic parameters and oxygenation before, during and after DETA/NO administration are summarized in Figures 1 and  2 . The initial PAP and PVRI values at 30 min and immediately before drug administration were 37 and 39 mmHg, and 824 and 723 dyn.s.cm -5 .m -2 , respectively (Figures 1a and 1b) . Both PAP and PVRI were reduced following DETA/NO delivery and remained low throughout the four hours of observation. There were no significant changes in either systemic vascular resistance index (SVRI) or SBP during the study period (Figures 1c and 1d ). Arterial methaemoglobin concentration did not increase after inhalation of DETA/NO aerosol and remained at less than 1% throughout the study period. Intrapulmonary shunting reduced from the initial 28% to 12%, 11% and 21.6% at 15, 30 and 45 min respectively after aerosol inhalation (Figure 2a ). However, the percentage of intrapulmonary shunting had returned to baseline levels by 60 min. Improvement in A-aDO 2 followed a similar time course to that for intrapulmonary shunting (Figure 2b) .
DISCUSSION
ARDS is an acute inflammatory syndrome characterized by increases in alveolar-capillary permeability and resultant hypoxaemia. The incidence of ARDS is approximately 10 in 100,000 population per year and the condition has a 35 to 50% mortality rate 6 . Lung function and health-related quality of life are signifi- 
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cantly reduced in survivors of ARDS 7, 8 . ARDS usually co-exists with acute pulmonary hypertension (APH), which can impact on immediate management and ultimately on morbidity and mortality 6,9 . In ARDS, increased intrapulmonary shunting is a common finding that may contribute to hypoxaemia 10 . We have previously shown the selective vasodilatory effect of aerosolized DETA/NO in a porcine model of APH (Lam et al, submitted for publication). Inhalation of 60 µmol DETA/NO significantly reduced APH that had been induced by the infusion of the prostaglandin H 2 /thromboxane A 2 receptor agonist (U46619). Compared with the controls, the pulmonary vasodilatory effect lasted for up to 60 min after aerosol administration and importantly had no significant effect on the systemic circulation. Intrapulmonary shunting and oxygenation tended to improve after treatment. Hampl et al has also previously demonstrated the selective pulmonary vasodilatory effect of aerosolized DETA/NO in a chronic pulmonary hypertension model in rats 11 .
The potential toxicity of aerosolized DETA/NO after single-dose and multiple-dose exposure has also been investigated in pigs and rats in our laboratory (Lam et al, submitted for publication). In pigs, acute aerosol administration of DETA/NO did not cause lung inflammation, oedema or increase of arterial concentration of methaemoglobin. In rats, repeated exposure to DETA/NO aerosol for up to seven days was again not associated with any increase in lung inflammation, oedema or blood concentration of surfactant protein B.
Compared to control values before treatment, there was a mean 26% (range 8-40%) reduction in PVRI and a mean 18% (range 8-29%) reduction in PAP, following aerosolized DETA/NO delivery. In addition, there were no significant changes in SBP, SVRI, CO or PAWP (mean changes were within 10% from control values before treatment). The vasodilatory actions of aerosolized DETA/NO were confined to the pulmonary vascular bed, presumably because the released NO from the parent compound is rapidly inactivated by haemoglobin once it enters the circulation. Furthermore, there was a reduction of intrapulmonary shunting and an improvement in A-aDO 2 , which lasted for between 45 and 60 min after inhalation.
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vasculature in both well-and under-ventilated lung regions. The increased return of deoxygenated blood, through the under-ventilated lung areas, increases intrapulmonary shunting and reduces oxygenation 3 . By contrast, when DETA/NO aerosol is inhaled, only the well-ventilated lung units receive the drug and it dilates predominately the pulmonary vasculature in these areas. Thus the improved ventilation/perfusion matching in the well-ventilated lung units reduces intrapulmonary shunting and improves overall oxygenation.
Due to the encouraging results from the initial animal studies, we resolved to test the haemodynamic and oxygenation effects of aerosolized DETA/NO in patients with severe ARDS. The selective vasodilatory effect of DETA/NO in the pulmonary circulation in this patient with ARDS was clearly demonstrated after the administration of a single aerosol dose. The responses seen in this patient suggest a future role for aerosolized DETA/NO in ARDS and other conditions where pulmonary hypertension and/or hypoxaemia are features. Use of this drug in a larger number of ARDS patients is required to determine its consistent benefits.
